Physician profile
Michelle Lee Willoby
NPI 1801864822
$11,365.77
in general payments reported to CMS, 2019-2025
49 companies · $1,735 in 2025
The $1,735 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $1,570 · 2021: $1,785 · 2022: $1,300 · 2023: $1,862 · 2024: $2,065 · 2025: $1,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,637 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,636.59 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,626.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,604.88 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,014.11 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $748.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $710.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $617.62 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $553.70 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $535.11 | 2019-2025 | Xifaxan |
| Amgen INC. | $436.86 | 2019-2025 | Evenity, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $335.10 | 2019-2025 | |
| Abbott Laboratories | $235.31 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $234.17 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $232.32 | 2019-2022 | |
| Allergan, INC. | $227.97 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.17 | 2023-2025 | Caplyta |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Willoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.